Optimi Health Secures Import Permit from Mind Medicine Australia for MDMA and Psilocybin Capsules
May 29, 2024 08:00 ET
|
Optimi Health Corp.
Optimi Health preparing to export 160 doses of MDMA and psilocybin under Australia’s Authorized Prescriber Scheme.
Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder
May 22, 2024 08:30 ET
|
Optimi Health Corp.
Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder
Optimi Health Provides Corporate Update
May 10, 2024 08:50 ET
|
Optimi Health Corp.
Optimi Health provides corporate update.
Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University's Institute for Psychedelic Research
May 09, 2024 08:00 ET
|
Optimi Health Corp.
Export Permit granted: Optimi's Shipment of MDMA active pharmaceutical ingredient (API) to Israel marks the Company’s first international export
PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy
May 03, 2024 11:00 ET
|
PharmAla Biotech
PharmAla launches new educational resource for prescribers of MDMA through the Special Access Program
Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research
April 23, 2024 08:18 ET
|
Optimi Health Corp.
Optimi Health announces innovative research and development partnership with the Kwantlen Polytechnic University Applied Genomics Centre.
PharmAla Closes Private Placement and Concurrent Debt Settlement
April 19, 2024 08:35 ET
|
PharmAla Biotech
PharmAla completes private placement and concurrent debt settlement with Advisor.
Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
April 15, 2024 08:00 ET
|
Optimi Health Corp.
Optimi announces completion of three batches of its MDMA API manufactured from raw materials under the Company’s Precursor Licence.
PharmAla Announces Private Placement and Concurrent Debt Settlement
April 10, 2024 16:30 ET
|
PharmAla Biotech
PharmAla Initiates $750,000 Private Placement with concurrent debt settlement, anticipated to close on April 17th 2024
Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
April 05, 2024 08:58 ET
|
PharmAla Biotech
PharmAla Biotech announces that its Australian Joint Venture, Cortexa, has initiated manufacturing of LaNeo MDMA in Australia.